GLP-2(3-33) (Leu-$^{13}C_6$,^{15}N)

Cat. No.:	HY-P2625S
Molecular Formula:	$C_{150}{}^{13}C_6H_{242}N_{39}{}^{15}NO_{53}S$
Molecular Weight:	3564.84
Sequence:	Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-{Leu-13C6,15N}-Ile-Gln-Thr-Lys-Ile-Thr-Asp
Sequence Shortening:	DGSFSDEMNTI-{Leu-13C6,15N}-DNLAARDFINWLIQTKITD
Target:	Isotope-Labeled Compounds
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	GLP-2(3-33) (Leu-$^{13}C_6$,^{15}N) is ^{13}C and ^{15}N labeled GLP-2(3-33) (HY-P2625). GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC_{50}=5.8 nM).
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA